BBIO
Price
$54.63
Change
+$1.76 (+3.33%)
Updated
Oct 6, 04:59 PM (EDT)
Capitalization
10.44B
24 days until earnings call
LIXT
Price
$5.06
Change
-$0.26 (-4.89%)
Updated
Oct 6, 04:59 PM (EDT)
Capitalization
23.03M
Interact to see
Advertisement

BBIO vs LIXT

Header iconBBIO vs LIXT Comparison
Open Charts BBIO vs LIXTBanner chart's image
BridgeBio Pharma
Price$54.63
Change+$1.76 (+3.33%)
Volume$26.87K
Capitalization10.44B
Lixte Biotechnology Holdings
Price$5.06
Change-$0.26 (-4.89%)
Volume$670
Capitalization23.03M
BBIO vs LIXT Comparison Chart in %
BBIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
LIXT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BBIO vs. LIXT commentary
Oct 07, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BBIO is a Hold and LIXT is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 07, 2025
Stock price -- (BBIO: $52.86 vs. LIXT: $5.32)
Brand notoriety: BBIO and LIXT are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BBIO: 55% vs. LIXT: 104%
Market capitalization -- BBIO: $10.44B vs. LIXT: $23.03M
BBIO [@Biotechnology] is valued at $10.44B. LIXT’s [@Biotechnology] market capitalization is $23.03M. The market cap for tickers in the [@Biotechnology] industry ranges from $103.3B to $0. The average market capitalization across the [@Biotechnology] industry is $2.05B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BBIO’s FA Score shows that 1 FA rating(s) are green whileLIXT’s FA Score has 0 green FA rating(s).

  • BBIO’s FA Score: 1 green, 4 red.
  • LIXT’s FA Score: 0 green, 5 red.
According to our system of comparison, BBIO is a better buy in the long-term than LIXT.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BBIO’s TA Score shows that 6 TA indicator(s) are bullish while LIXT’s TA Score has 3 bullish TA indicator(s).

  • BBIO’s TA Score: 6 bullish, 2 bearish.
  • LIXT’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, BBIO is a better buy in the short-term than LIXT.

Price Growth

BBIO (@Biotechnology) experienced а +5.61% price change this week, while LIXT (@Biotechnology) price change was +5.14% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.32%. For the same industry, the average monthly price growth was +14.86%, and the average quarterly price growth was +84.67%.

Reported Earning Dates

BBIO is expected to report earnings on Oct 30, 2025.

Industries' Descriptions

@Biotechnology (+7.32% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BBIO($10.4B) has a higher market cap than LIXT($23M). LIXT YTD gains are higher at: 162.108 vs. BBIO (92.638). LIXT has higher annual earnings (EBITDA): -3.08M vs. BBIO (-643.59M). BBIO has more cash in the bank: 757M vs. LIXT (887K). LIXT has less debt than BBIO: LIXT (100K) vs BBIO (1.86B). BBIO has higher revenues than LIXT: BBIO (236M) vs LIXT (0).
BBIOLIXTBBIO / LIXT
Capitalization10.4B23M45,217%
EBITDA-643.59M-3.08M20,906%
Gain YTD92.638162.10857%
P/E RatioN/AN/A-
Revenue236M0-
Total Cash757M887K85,344%
Total Debt1.86B100K1,858,000%
FUNDAMENTALS RATINGS
BBIO vs LIXT: Fundamental Ratings
BBIO
LIXT
OUTLOOK RATING
1..100
5397
VALUATION
overvalued / fair valued / undervalued
1..100
3
Undervalued
76
Overvalued
PROFIT vs RISK RATING
1..100
76100
SMR RATING
1..100
99100
PRICE GROWTH RATING
1..100
4035
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BBIO's Valuation (3) in the null industry is significantly better than the same rating for LIXT (76). This means that BBIO’s stock grew significantly faster than LIXT’s over the last 12 months.

BBIO's Profit vs Risk Rating (76) in the null industry is in the same range as LIXT (100). This means that BBIO’s stock grew similarly to LIXT’s over the last 12 months.

BBIO's SMR Rating (99) in the null industry is in the same range as LIXT (100). This means that BBIO’s stock grew similarly to LIXT’s over the last 12 months.

LIXT's Price Growth Rating (35) in the null industry is in the same range as BBIO (40). This means that LIXT’s stock grew similarly to BBIO’s over the last 12 months.

LIXT's P/E Growth Rating (100) in the null industry is in the same range as BBIO (100). This means that LIXT’s stock grew similarly to BBIO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BBIOLIXT
RSI
ODDS (%)
N/A
Bearish Trend 4 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 4 days ago
76%
Bullish Trend 4 days ago
90%
Momentum
ODDS (%)
Bullish Trend 4 days ago
79%
Bearish Trend 4 days ago
90%
MACD
ODDS (%)
Bullish Trend 4 days ago
75%
Bearish Trend 4 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 4 days ago
79%
Bullish Trend 4 days ago
86%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
82%
Bullish Trend 4 days ago
87%
Advances
ODDS (%)
Bullish Trend 8 days ago
80%
Bullish Trend 25 days ago
84%
Declines
ODDS (%)
Bearish Trend 4 days ago
84%
Bearish Trend 6 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 4 days ago
74%
Bearish Trend 4 days ago
90%
Aroon
ODDS (%)
Bullish Trend 4 days ago
73%
Bullish Trend 4 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
BBIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
LIXT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
AHLT24.800.34
+1.40%
American Beacon AHL Trend ETF
BKUI49.78N/A
N/A
BNY Mellon Ultra Short Income ETF
CADHKD5.57-0.00
-0.02%
Canadian Dollar - Hong Kong Dollar
AWF11.09-0.03
-0.27%
ALLIANCEBERSTEIN GLOBAL HIGH Income FUND
CNYGBP0.10-0.00
-0.68%
China Yuan - United Kingdom Pound